

**Final Comments Luteinizing Hormone-Releasing Hormone (LHRH) Analogs  
INJ-039**

**Contractor's comment:** Luteinizing Hormone-Releasing Hormone (LHRH) Analogs  
The title of this LCD has been changed from Gonadotropin-Releasing Hormone Analogs for the states of Wisconsin, Illinois, Michigan and Minnesota to Luteinizing Hormone-Releasing Hormone (LHRH) Analogs

**Comment:**

A pharmaceutical company agrees with the recognition in the LCD that Degarelix is a GnRH receptor antagonist and is distinctive from the LHRH agonists/analogs drugs that are subject to LCA provisions addressed in this LCD.

**Response:**

The following statement is included in this LCD for clarification;

*Degarelix, for the treatment of prostate cancer, antagonizes the gonadotropin-releasing hormone (GnRH) receptors and thus is not addressed in this LCD. Therefore, degarelix is not subject at this time, to the least costly alternative instructions provided in this LCD*

**Comment:**

A request to modify the language in the LCD to reflect the language in the Billing and Coding Guidelines was evaluated. The request specifically asked that the statement “pricing will be crosswalked only among similar interval drugs; e.g. one month pricing will not be crosswalked to 1/12 of one year pricing,” and additional distinctions be added to the LCD.

**Response**

The intent of the coding and billing article referenced in the query above is meant to provide additional information and direction. Therefore, WPS Medicare does not at this time see any valid reason to modify statements found within the LCD.